Small Non-cleaved Cell Lymphoma News

Small Non-cleaved Cell Lymphoma	Welcome, Profile Billing Logout

«1 2...2 3 4 5 6 7 8910 11 12 13 14 »

||||||||||  Rituxan (rituximab) / Roche
Trial completion:  Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma (clinicaltrials.gov) -  Feb 5, 2014
P2, N=34, Completed,  Sponsor: AIDS Malignancy Clinical Trials Consortium
Active, not recruiting --> Completed

||||||||||  Rytelo (imetelstat) / Geron
Enrollment change:  Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) -  Jan 28, 2014
P1, N=34, Completed,  Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=45 --> 34

||||||||||  Rytelo (imetelstat) / Geron
Trial completion:  Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma (clinicaltrials.gov) -  Jan 28, 2014
P1, N=34, Completed,  Sponsor: Children's Oncology Group
N=45 --> 34 Active, not recruiting --> Completed

||||||||||  lapatinib / Generic mfg., everolimus / Generic mfg.
Enrollment change, Metastases:  S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Jan 21, 2014
P1, N=66, Completed,  Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=48 --> 66

||||||||||  lapatinib / Generic mfg., everolimus / Generic mfg.
Trial completion, Metastases:  S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Jan 21, 2014
P1, N=66, Completed,  Sponsor: Southwest Oncology Group
N=48 --> 66 Active, not recruiting --> Completed

||||||||||  alisertib (MLN8237) / Puma
Enrollment change:  MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine (clinicaltrials.gov) -  Jan 19, 2014
P1/2, N=43, Active, not recruiting,  Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=100 --> 43

||||||||||  alisertib (MLN8237) / Puma
Enrollment closed:  MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine (clinicaltrials.gov) -  Jan 19, 2014
P1/2, N=43, Active, not recruiting,  Sponsor: Millennium Pharmaceuticals, Inc.
N=100 --> 43 Recruiting --> Active, not recruiting

||||||||||  Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Enrollment closed:  Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Jan 14, 2014
P1/2, N=58, Active, not recruiting,  Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  Ixempra (ixabepilone) - Otsuka, R / Pharm, patupilone (EPO 906) / Novartis
Enrollment change:  Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Jan 9, 2014
P2, N=52, Completed,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=76 --> 52

|||||||||| Enrollment change, Metastases: FAU in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 5, 2014
P1, N=12, Completed, Sponsor: National Cancer Institute (NCI)
N=76 --> 52 N=49 --> 12

|||||||||| Trial completion, Metastases: FAU in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 5, 2014
P1, N=12, Completed, Sponsor: National Cancer Institute (NCI)
N=49 --> 12 Suspended --> Completed

||||||||||  Copiktra (duvelisib) / Secura Bio, Yakult Honsha
New P2 trial:  IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) -  Jan 2, 2014
P2, N=0, Withdrawn,  Sponsor: M.D. Anderson Cancer Center

|||||||||| Trial initiation date, Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Suspended --> Completed Initiation date: Oct 2013 --> Oct 2014

||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Enrollment change:  Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) -  Jan 1, 2014
P=N/A, N=153, Completed,  Sponsor: City of Hope Medical Center
Initiation date: Oct 2013 --> Oct 2014 N=300 --> 153

||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Trial completion:  Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) -  Jan 1, 2014
P=N/A, N=153, Completed,  Sponsor: City of Hope Medical Center
N=300 --> 153 Suspended --> Completed

||||||||||  fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Enrollment open, Combination therapy, IO biomarker, Post-transplantation:  Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) -  Dec 19, 2013
P1, N=20, Recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Suspended --> Completed Active, not recruiting --> Recruiting

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion:  Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia (clinicaltrials.gov) -  Dec 17, 2013
P2, N=120, Completed,  Sponsor: Medical Research Council
Active, not recruiting --> Recruiting Active, not recruiting --> Completed

||||||||||  Promune (agatolimod) / Pfizer, Rituxan (rituximab) / Roche
Trial completion:  Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) -  Dec 16, 2013
P1, N=0, Completed,  Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Rituxan (rituximab) / Roche
Trial completion:  Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies (clinicaltrials.gov) -  Nov 24, 2013
P2, N=54, Completed,  Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Yervoy (ipilimumab) / BMS
Trial suspension, Combination therapy:  Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) -  Nov 18, 2013
P1/2, N=69, Suspended,  Sponsor: Stanford University
Active, not recruiting --> Completed Recruiting --> Suspended

||||||||||  cyclophosphamide / Generic mfg.
New P2 trial:  Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Oct 30, 2013
P2, N=20, Recruiting,  Sponsor: National University Health System, Singapore

||||||||||  ontuxizumab (MORAb-004) / Eisai
Enrollment open:  MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) -  Oct 30, 2013
P1, N=65, Recruiting,  Sponsor: Morphotek
Recruiting --> Suspended Not yet recruiting --> Recruiting

|||||||||| Enrollment closed, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Oct 30, 2013
P2, N=42, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

||||||||||  cyclophosphamide / Generic mfg.
Enrollment open:  Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Oct 26, 2013
P2, N=20, Recruiting,  Sponsor: National University Health System, Singapore
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial termination:  Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) -  Oct 21, 2013
P2, N=1, Terminated,  Sponsor: Barbara Ann Karmanos Cancer Institute
Not yet recruiting --> Recruiting Suspended --> Terminated; Lack of funding.

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change:  Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) -  Oct 21, 2013
P2, N=1, Terminated,  Sponsor: Barbara Ann Karmanos Cancer Institute
Suspended --> Terminated; Lack of funding. N=61 --> 1

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
Clinical:  Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant (clinicaltrials.gov) -  Oct 21, 2013
P2, N=39, Active, not recruiting,  Sponsor: Children's Oncology Group
N=61 --> 1 Completed --> Active, not recruiting

|||||||||| Enrollment change: Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients (clinicaltrials.gov) - Oct 20, 2013
P=N/A, N=175, Completed, Sponsor: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Completed --> Active, not recruiting N=100 --> 175

|||||||||| Trial completion: Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients (clinicaltrials.gov) - Oct 20, 2013
P=N/A, N=175, Completed, Sponsor: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
N=100 --> 175 Recruiting --> Completed

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Enrollment open:  Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) -  Oct 13, 2013
P2, N=12, Recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Rituxan (rituximab) / Roche
Enrollment closed, Post-transplantation:  Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) -  Oct 7, 2013
P2, N=100, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

||||||||||  Rituxan (rituximab) / Roche
Trial termination:  Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Oct 6, 2013
P2, N=82, Terminated,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Completed --> Terminated

||||||||||  Rituxan (rituximab) / Roche
Trial initiation date:  Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Oct 6, 2013
P2, N=82, Terminated,  Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Initiation date: Feb 2003 --> Nov 2003

||||||||||  MK-2206 / Merck (MSD)
Trial completion:  MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) -  Sep 26, 2013
P1, N=45, Completed,  Sponsor: National Cancer Institute (NCI)
Initiation date: Feb 2003 --> Nov 2003 Active, not recruiting --> Completed

||||||||||  sunitinib / Generic mfg.
Trial completion:  Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (clinicaltrials.gov) -  Sep 26, 2013
P1, N=42, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Triapine (3-AP) / Vion, Northwestern University
Trial completion, Combination therapy, Metastases:  3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) -  Sep 26, 2013
P1, N=30, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed:  Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells (clinicaltrials.gov) -  Sep 23, 2013
P2, N=20, Active, not recruiting,  Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Enrollment open:  Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) -  Sep 22, 2013
P1, N=30, Recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

||||||||||  Rituxan (rituximab) / Roche
Enrollment change:  Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease (clinicaltrials.gov) -  Sep 12, 2013
P1, N=2, Terminated,  Sponsor: University of Medicine and Dentistry New Jersey
Not yet recruiting --> Recruiting N=20 --> 2

||||||||||  Rituxan (rituximab) / Roche
Trial termination:  Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) -  Sep 10, 2013
P2, N=3, Terminated,  Sponsor: Fred Hutchinson Cancer Research Center
N=20 --> 2 Recruiting --> Terminated; Low accrual

||||||||||  Rituxan (rituximab) / Roche
Enrollment change:  Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) -  Sep 10, 2013
P2, N=3, Terminated,  Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Terminated; Low accrual N=50 --> 3

|||||||||| Trial completion, HEOR: Quality of Life in Children Treated for Cancer (clinicaltrials.gov) - Aug 21, 2013
P=N/A, N=538, Completed, Sponsor: Children's Oncology Group
N=50 --> 3 Active, not recruiting --> Completed

||||||||||  melphalan / Generic mfg.
Enrollment closed:  Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases (clinicaltrials.gov) -  Aug 14, 2013
P2, N=70, Active, not recruiting,  Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

|||||||||| Trial completion: Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 5, 2013
P3, N=200, Completed, Sponsor: Cancer Research Campaign Clinical Trials Centre
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Trial withdrawal, Virus specific T cells: Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants (clinicaltrials.gov) - Aug 1, 2013
P1, N=0, Withdrawn, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Completed --> Withdrawn

||||||||||  Leukine (sargramostim) / Partner Therap
Trial termination:  Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (clinicaltrials.gov) -  Jul 31, 2013
P1, N=3, Terminated,  Sponsor: Dartmouth-Hitchcock Medical Center
Completed --> Withdrawn Active, not recruiting --> Terminated; Medarex (supplier of BsAb) stopped study due to toxicities experienced at other sites on unrelated trials halting manufacturing of BsAb

||||||||||  levofloxacin / Generic mfg.
Trial completion:  CRC-TU-SIGNIFICANT: Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma (clinicaltrials.gov) -  Jul 31, 2013
P3, N=0, Completed,  Sponsor: Cancer Research Campaign Clinical Trials Centre
Active, not recruiting --> Terminated; Medarex (supplier of BsAb) stopped study due to toxicities experienced at other sites on unrelated trials halting manufacturing of BsAb Active, not recruiting --> Completed

||||||||||  Rituxan (rituximab) / Roche
Trial termination:  Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Jul 30, 2013
P1/2, N=52, Terminated,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated; NCI stopped supplying fenretinide in November of 2012.

||||||||||  melphalan / Generic mfg.
Enrollment change:  Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases (clinicaltrials.gov) -  Jul 9, 2013
P2, N=70, Active, not recruiting,  Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Terminated; NCI stopped supplying fenretinide in November of 2012. N=40 --> 70

||||||||||  alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
New P1 trial:  Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) -  Jul 9, 2013
P1, N=30, Recruiting,  Sponsor: National Cancer Institute (NCI)



	Diseases Companies Products Productz Mechanisms of Action Sites